ObjectiveTo systematically review the clinical significance of Raman spectroscopy (RS) in the auxiliary diagnosis of colon cancer (CC). MethodsPubMed, Web of Science, The Cochrane Library, CNKI, VIP and WanFang Data databases were electronically searched to collect diagnostic tests related to RS in the auxiliary diagnosis of CC from inception to October 1st, 2021. Two reviewers independently screened the literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed using Stata 12.0 and Meta-Disc 1.4 software. ResultsA total of 21 studies involving 1 419 patients were included. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and positive posttest probability (PPP) for CC screening applying RS were 0.94 (95%CI 0.93 to 0.95), 0.91 (95%CI 0.90 to 0.92), 157.50 (95%CI 74.44 to 333.21), 10.40 (95%CI 6.62 to 16.33), 0.08 (95%CI 0.05 to 0.12) and 77%, respectively. The area under the curve (AUC) of summary receiver operating characteristic (SROC) curve was 0.98 (95%CI 0.96 to 0.99). ConclusionCurrent evidence shows that RS is a potentially useful tool for CC screening. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to verify the above conclusion.
Objective To systematically evaluate the efficacy and safety of duloxetine versus paroxetine for adults’ depression. Methods A search was conducted in The Cochrane Library (Issue 6, 2011), Pubmed (1998 to June 2011), CNKI (1998 to June 2011), VIP (1998 to June 2011), CBM (1998 to June 2011), Wanfang database (1998 to June 2011), MEDLINE (1996 to June 2011) and Science Direct (1998 to June 2011). The randomized controlled trials (RCTs) on duloxetine versus paroxetine for adults’ depression were collected. The quality of the included trials was assessed according to the Cochrane Handbook 5.0, and the systematic analysis was conducted by using RevMan 5.0 software. Results Six RCTs involving 1 106 patients were included. The results of meta-analysis showed that: a) After eight-week treatment, there were no significant differences in the effective rate (RR=0.96, 95%CI 0.89 to 1.05, P=0.39) and the final cure rate (RR=0.99, 95%CI 0.86 to 1.15, P=0.93) between the duloxetine and paroxetine groups; b) Adverse reaction: The incidence rate of somnolence in the duloxetine group was lower than that of the paroxetine group (RR=0.63, 95%CI 0.41 to 0.96, P=0.03), oppositely, the incidence rate of abnormal ECG was higher in the duloxetine group (RR=1.91, 95%CI, 1.02 to 3.58, P=0.04). And the other common adverse reactions were not significantly different between the two groups (Pgt;0.05). Conclusion After eight-week treatment, there are no significant differences in the effective rate and the final cure rate between duloxetine and paroxetine. Duloxetine tends easily to induce the abnormal ECG compared with paroxetine.